Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar posts strong clinical data but losses widen as it advances late-stage trials.

What the company is saying

Cellectar Biosciences, led by CEO James Caruso, emphasizes progress toward registering and commercializing iopofosine I 131 for Waldenström macroglobulinemia. The company highlights new Phase 2b efficacy data showing an 87.5% overall response rate, 79.2% major response rate, and 100% clinical benefit rate in post-BTK inhibitor patients, with a median response duration of 16.0 months and treatment-free survival of 19.1 months. Less than 10% of patients experienced treatment-emergent adverse events, with only cytopenias reaching Grade 3 or higher. Cellectar frames 2027 as a year of 'significant value creation,' citing a planned Phase 3 trial (100 patients per arm) and a New Drug Application submission in the first half of 2027. The company also points to a Phase 1b dosimetry trial in WM, a case study of a durable complete response in DLBCL, and ongoing CLR 125 trials in triple-negative breast cancer. Financially, the company stresses a cash balance of $24.6 million as of September 30, 2026, following a $31.7 million capital raise in May, and asserts this is sufficient to fund operations into Q2 2027. The tone is confident, with forward-looking statements about multiple upcoming milestones.

What the data suggests

Cellectar's financials show a net loss of $8.0 million ($0.46 per share) for Q3 2026, up from $4.4 million ($1.41 per share) in Q3 2025, driven by R&D expenses rising to $5.4 million from $2.5 million and G&A expenses increasing to $2.7 million from $2.3 million. Cash and cash equivalents rose to $24.6 million as of September 30, 2026, from $13.2 million at year-end 2025, due to $31.7 million in net proceeds from a May 2026 offering. The company projects this cash will fund operations into the second quarter of 2027. Operationally, the company has not yet dosed patients in its pivotal Phase 3 trial, but has activated initial sites and expects first dosing in Q1 2027. The Phase 1b dosimetry trial in WM is underway, with data expected from 20–30 patients. The CLR 125 program in TNBC is enrolling, with initial data expected in Q4 2026. No revenue is reported, and the accumulated deficit stands at $289.7 million. The clinical data presented are robust for the Phase 2b WM cohort, but all commercial and regulatory milestones remain forward-looking.

Analysis

The announcement is upbeat, highlighting strong Phase 2b efficacy data and progress toward late-stage clinical milestones. However, half of the key claims are forward-looking, including the planned Phase 3 trial, NDA submission, and future data presentations, none of which have yet occurred. The company has recently raised $31.7 million and is increasing R&D spend, but remains pre-revenue and continues to report widening net losses, with no commercial returns expected before at least mid-2027. While the clinical data presented is specific and credible for the company's stage, the narrative inflates near-term value creation by emphasizing 'significant milestones' and 'value creation' in 2027, despite the long and uncertain path to regulatory approval and commercialization. The capital outlay is substantial relative to the company's cash runway, and the benefits are not imminent. The tone is moderately hyped but not egregiously so, as the technical disclosures are detailed and appropriate for a late-stage biotech.

Risk flags

• ●Cellectar remains pre-revenue and is incurring widening net losses, with a Q3 2026 net loss of $8.0 million and an accumulated deficit of $289.7 million, increasing dependence on external capital to sustain operations.
• ●The company's cash runway, at $24.6 million as of September 30, 2026, is projected to last only into the second quarter of 2027, leaving little margin for delays in clinical or regulatory milestones before further dilution or financing is needed.
• ●All major value inflection points, including Phase 3 patient dosing, pivotal data, and NDA submission, are scheduled for 2027, so any delay or negative trial outcome could materially impact prospects before commercialization.
• ●The strong Phase 2b efficacy data are based on a subset of 24 evaluable patients, which may not fully predict outcomes in the larger, randomized Phase 3 trial, especially given the complexity of the post-BTKi WM population.
• ●R&D and G&A expenses are rising sharply, with R&D more than doubling year-over-year, increasing the risk that operational costs could outpace available funding if timelines slip.

Bottom line

Cellectar is advancing iopofosine I 131 with compelling Phase 2b data in a difficult-to-treat WM population, but remains pre-commercial with widening losses and a finite cash runway. The company has raised $31.7 million to fund late-stage trials, but will need to execute flawlessly on its Phase 3 and regulatory timelines to avoid additional dilution. The next concrete milestones are patient dosing in Q1 2027 and NDA submission in the first half of 2027, with no commercial revenue likely before then. Investors should weigh the promising clinical data against the operational and financial risks of a single-asset, late-stage biotech facing a tight funding window and uncertain regulatory outcomes. The most important takeaway is that while the clinical results are strong, the path to value realization is capital-intensive and highly execution-dependent over the next 12–18 months.

Announcement summary

(NASDAQ:CLRB) Cellectar Biosciences, Inc. announced its financial results for the quarter ended September 30, 2026, and provided a comprehensive corporate update. James Caruso, president and chief executive officer, stated the company remains focused on advancing iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia (WM). New sub-analysis efficacy data from the Phase 2b CLOVER-WaM trial were presented at the International Workshop for Waldenström Macroglobulinemia (IWWM), showing an overall response rate (ORR) of 87.5%, a major response rate (MRR) of 79.2%, a median duration of response (DoR) of 16.0 months, treatment free survival (TFS) of 19.1 months, and a clinical benefit rate (CBR) of 100% in patients treated immediately after BTKi therapy. Less than 10% of patients experienced treatment emergent adverse events (TEAE), with cytopenias being the only Grade 3 or higher TEAE. The company plans to present three posters at the American Society of Hematology Annual Meeting and Exposition (ASH 2026), including updated 12-month follow-up data and a new analysis showing longer duration of response in patients treated after only two prior lines of therapy. Preparations for the Phase 3 confirmatory trial of iopofosine I 131 in WM are advanced, with initial clinical trial sites activated; the trial will randomize 100 WM patients per arm and evaluate progression-free survival as the primary endpoint. The first patient is expected to be dosed in Q1 2027, and a New Drug Application (NDA) submission to the FDA is planned for the first half of 2027 seeking accelerated approval. The Phase 1b dosimetry trial of iopofosine I 131 in all WM treatment lines has been initiated, with data expected from 20-30 newly diagnosed and relapsed WM patients. A case study was reported of a 53-year-old patient with high-grade, double-hit diffuse large B-cell lymphoma (DLBCL) achieving a complete response lasting more than eight years after iopofosine I 131 treatment. The CLR 121125 (CLR 125) iodine-125 program for solid tumors continues enrolling in a Phase 1b trial for refractory triple-negative breast cancer (TNBC), with initial dosimetry and safety data expected in Q4 2026. The company hosted a webinar on its Phospholipid Drug Conjugate (PDC) platform, highlighting its potential for combining with various therapeutic molecules. As of September 30, 2026, cash and cash equivalents were $24,582,115, up from $13,196,033 at December 31, 2025, reflecting net proceeds of approximately $31.7 million from a May 2026 offering. The company believes this cash is adequate to fund operations into Q2 2027. Research and development expenses for Q3 2026 were $5,435,796, compared to $2,523,305 in Q3 2025, primarily due to the Phase 3 trial initiation and increased activity in the CLR 125 trial. General and administrative expenses for Q3 2026 were $2,668,219, up from $2,327,391 in Q3 2025, mainly due to higher professional fees and personnel costs. Net loss attributable to common stockholders for Q3 2026 was $7,974,743, or $0.46 per share, compared to $4,443,877, or $1.41 per share, in Q3 2025. Total assets as of September 30, 2026, were $29,743,263, with total liabilities of $7,327,897 and total stockholders’ equity of $22,415,366. The company had 10,039,183 shares of common stock issued and outstanding as of September 30, 2026. Weighted-average common shares outstanding for Q3 2026 were 17,462,898. The company will host a conference call and webcast on November 10, 2026, at 8:30 AM Eastern Time to discuss these results.

Disagree with this article?